公开(公告)号：US20240122865A1

公开(公告)日：2024-04-18

申请号：US18275634

申请日：2022-02-15

Applicant: Pfizer Inc.

Inventor： Justin Leigh Bellenger ,  Ye Che ,  Miguel Angel Garcia ,  Lei Hu ,  Mark Carl Noe ,  Shuai Shi

IPC: A61K9/51 ,  A61K9/48 ,  A61K39/12

CPC classification number: A61K9/5123 ,  A61K9/4858 ,  A61K39/12

Abstract: The present disclosure provides methods of protecting ribonucleic acid (RNA) from degradation under certain conditions by contacting the RNA with an amino acid. The present disclosure also provides compositions comprising such amino acid(s) and RNA.

公开(公告)号：US20240189410A1

公开(公告)日：2024-06-13

申请号：US18535116

申请日：2023-12-11

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Marina A. Gonzalez-Garis ,  Lei Hu ,  Isis Kanevsky ,  Paul Arthur Liberator ,  Justin Keith Moran ,  Lynn Marie Phelan ,  Michael William Pride ,  Shuai Shi ,  Naveen Surendran

IPC: A61K39/08 ,  A61K39/39 ,  A61P31/04

CPC classification number: A61K39/08 ,  A61K39/39 ,  A61P31/04 ,  A61K2039/55561

Abstract: The present invention relates to immunogenic compositions that comprise a Clostridioides difficile toxoid A and/or a C. difficile toxoid B, and an adjuvant, and methods of use thereof. The present invention further relate to a methods for eliciting an enhanced immune response in a human against a C. difficile infection. The methods include administering to the human an effective dose of an immunogenic composition, which includes a C. difficile toxoid and an adjuvant, wherein the composition is administered two times.